Clinical Research Directory
Browse clinical research sites, groups, and studies.
Cannabis (THC vs. CBD) in Multiple Sclerosis
Sponsor: University of Calgary
Summary
The goal of this clinical trial is to examine the effect of Cannabis components, THC and CBD, on cognition and bladder symptoms in people with Multiple Sclerosis (MS). Participants will complete questionnaires and cognitive tests. They will be randomly assigned to receive either CBD or THC oil and will take the study drug for 15 weeks.
Official title: The Differential Effects of THC vs. CBD on Cognition in Persons With MS
Key Details
Gender
All
Age Range
18 Years - 59 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2025-12-05
Completion Date
2026-09
Last Updated
2026-01-14
Healthy Volunteers
No
Conditions
Interventions
THC
Participants will be randomly assigned to the study treatment. THC dose will be gradually increased until 25 mg. Treatment will be taken orally at bedtime for 15 weeks.
CBD
Participants will be randomly assigned to the study treatment. CBD dose will be gradually increased until 50 mg. Treatment will be taken orally at bedtime for 15 weeks.
Locations (1)
University of Calgary
Calgary, Alberta, Canada